FATE Q1 2019 Earnings — Fate Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

FATEFate Therapeutics, Inc.

$142M

Q1 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$3M+156.5% YoY

Gross Profit

-$15M-573.6% margin

Operating Income

-$20M-776.8% margin

Net Income

-$20M-750.8% margin

EPS (Diluted)

$-0.30

QoQ Revenue Growth

+58.5%

Cash Flow

Operating Cash Flow

-$17M

Free Cash Flow

-$19M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$221M

Total Liabilities

$75M

Stockholders' Equity

$146M

Cash & Equivalents

$183M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$3M	$1M	+156.5%
Gross Profit	-$15M	-$10M	-44.5%
Operating Income	-$20M	-$14M	-45.5%
Net Income	-$20M	-$14M	-39.8%